$10.74
-0.37%
2026-09-04 10:43:33 EDT-$0.04
헬스케어
의료 - 진단 & 연구
NASDAQ
활발히 거래 중
중국 광저우에 본사를 두고 2014년에 설립된 Burning Rock Biotech Limited는 중국 인민공화국 내에서 암 치료 선택을 위한 진단 솔루션을 개발하고 제공하는 데 ...
중국 광저우에 본사를 두고 2014년에 설립된 Burning Rock Biotech Limited는 중국 인민공화국 내에서 암 치료 선택을 위한 진단 솔루션을 개발하고 제공하는 데 ...
•Key-man risk due to founder control
•Competitive biotech environment in China
•Ongoing path to consistent profitability
•Growth in precision medicine and NGS diagnostics
•Strong clinical validation of technology
•Founder's active personal financial alignment
Yusheng Han founded Burning Rock in 2014 to apply NGS technology to precision oncology in China, driven by a vision to improve cancer patient outcomes.
첫 기회: Founded Burning Rock Biotech in 2014 after gaining extensive experience in the life sciences sector.
CEO가 되기까지: Han leveraged his deep experience in life sciences to identify the gap in clinical-grade NGS testing in the Chinese oncology market, successfully taking the company from a startup to a publicly traded entity on the NASDAQ.
초기 비전: To guard life via science by providing high-quality, clinical-grade precision oncology testing.
Yusheng Han established Burning Rock to address the urgent need for advanced diagnostic tools in oncology. His leadership has been defined by a focus on clinical validation and commercial scale-up of NGS-based tests, consistently steering the company through the complexities of the Chinese regulatory environment and global capital markets.
Yusheng Han is a strong, technically focused leader who has built a credible brand in oncology diagnostics. While the company faces the typical hurdles of a growth-stage biotech, Han's ongoing...
A long-time life sciences professional who transitioned from industry experience to founding a specialized oncology diagnostics company.
이니셔티브: Founder, Chairman & CEO
기간: 2014–Present
사건: Successfully launched the company, navigated clinical trials, achieved regulatory approvals, and took the company public.
결과: Facing ongoing operational and financial pressures typical of the biotech sector.
Han continues to drive commercialization of precision diagnostics while actively demonstrating personal financial commitment to the firm.
매출: Focuses on NGS-based precision oncology test revenue with fluctuating quarterly results.
수익성: The company remains in a growth and investment phase, actively managing high R&D and operational costs.
주가: Stock performance has been volatile, common for growth-stage biotech companies in the current macroeconomic environment.
Han is a hands-on founder-CEO who emphasizes scientific rigor and strategic alignment.
스타일: hands-on operator
Yusheng Han balances his role as a technical visionary with an executive focus on clinical-grade standard setting. His management style involves close oversight of research and development coupled with active engagement in corporate governance. He has built a team centered around scientific expertise to navigate the complex regulatory landscapes for NGS diagnostic products.
Han demonstrates prudent capital management by aligning executive actions with shareholder interests, including open-market stock purchases.
Focuses on targeted investments in clinical-grade diagnostic innovation while managing operating expenses.
Capital allocation strategy under Han remains focused on R&D for NGS tests and market penetration. He has shown personal confidence in the company's trajectory, evidenced by frequent recent open-market purchases of ADSs, signaling a commitment to long-term value creation despite short-term market fluctuations.
Successful track record of capital raises through equity markets to support clinical R&D.
IPO · Undisclosed: Successful listing on NASDAQ
희석: moderate
Han has navigated multiple stages of financing, successfully transitioning the firm from private venture capital to public equity markets. Investor confidence is maintained through consistent reporting and clinical progress.
Han maintains significant influence through a dual-class share structure.
복수의결권 주식: 예
주식 클래스 상세: Class B shares carry superior voting rights, allowing Han to retain operational control.
의결권 지배력: 54.6%
Yusheng Han controls the company through his exclusive ownership of Class B shares. While this provides him with strategic flexibility, it limits the voting power of minority shareholders in the Class A ADSs. Governance focuses on board-level compliance and transparency in clinical outcomes.
No public concerns; founder is actively involved.
건강 상태: no public concerns
승계 계획 공시: 아니오
핵심 인물 리스크: High
As a founder-controlled entity, the company faces significant key-man risk.
R&D is the core of the company, with a focus on NGS technology application in oncology.
High, central to the company's competitive advantage.
Clinical-grade NGS diagnostics: Ongoing, successful in validating clinical utility
High; strongly aligned with precision oncology trends.
Han prioritizes high-investment in technical pipeline, ensuring that test accuracy meets the highest medical standards. The innovation culture is driven by the goal to expand the range of cancers diagnosed by their platforms.
Attracts scientific talent through its focus on clinical research and impact.
Strong bench in clinical science and oncology.
유지율: Strong
The recruitment strategy is centered on building a team with expertise in oncology, NGS, and clinical research. Retention is bolstered by the firm's leadership in the field and its academic partnership base.
Deep technical knowledge and an unwavering commitment to clinical validation.
Technical Vision: Pioneered the application of clinical-grade NGS in the Chinese oncology market.
Operating in a highly competitive and regulated environment creates persistent profitability challenges.
Profitability
Struggles to reach consistent net profitability in a cash-intensive sector.
예시: Ongoing quarterly financial pressures
Brand strength is built on clinical-grade scientific reliability and academic validation.
The company has established itself as a reliable brand for precision oncology diagnostics in China.
Marketing focuses on scientific evidence and partnerships with major medical institutions. The brand is positioned around accuracy and clinical impact, targeting oncologists and hospital networks to drive adoption of NGS testing products.
Professional, data-driven, and transparent in communications regarding financial and clinical milestones.
미디어 평판: positive
Communications emphasize technical milestones and clinical trial data. Earnings calls are typically factual and focused on long-term strategy, with a consistent effort to explain the value proposition of NGS to stakeholders.